Roche Bids $4.3 Billion for U.S.-Based Gene Therapy Specialist Spark

Roche Holding AG’s $4.8 billion bid for Spark Therapeutics Inc. raises the stakes further in the bidding for makers of therapies that promise to treat rare, debilitating diseases by correcting inborn flaws in DNA. Purchasing Philadelphia-based Spark will put Roche near the front of the pack with Basel-based neighbor Novartis AG in developing the promising […]